Trial record 1 of 1 for:
NCT04972721
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial (SELECT-LIFE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04972721 |
|
Recruitment Status :
Recruiting
First Posted : July 22, 2021
Last Update Posted : February 29, 2024
|
Sponsor:
Novo Nordisk A/S
Information provided by (Responsible Party):
Novo Nordisk A/S
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial.
SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends.
SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial including the trial medicine participants have been taking.
When the SELECT trial ends, participants will no longer get the medicine participants got in the study, even if participants decide to take part in the SELECT-LIFE study.
Participants will not get any specific treatment or medicine as part of the SELECT-LIFE study, and participants will be treated as participants normally would by their own doctor.
The SELECT-LIFE study will last for up to 10 years after SELECT trial ends, and participants will be asked to fill in a questionnaire about their health every 6 months.
| Condition or disease | Intervention/treatment |
|---|---|
| Overweight Obesity | Other: No treatment given |
| Study Type : | Observational |
| Estimated Enrollment : | 3400 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | SELECT-LIFE (SELECT Follow-up Study to Evaluate Long-term Impact oF Anti-obEsity Medication) |
| Actual Study Start Date : | September 1, 2023 |
| Estimated Primary Completion Date : | April 1, 2032 |
| Estimated Study Completion Date : | November 30, 2033 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Questionnaire survey
Participants of the SELECT trial (EX9536-4388 ) are invited to transition to SELECT-LIFE (follow-up study) when SELECT ends.
|
Other: No treatment given
The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion. |
Primary Outcome Measures :
- Time to all-cause death [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Time to first occurrence of a composite consisting of: All-cause death, non-fatal myocardial infarction and non-fatal stroke [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Time to first occurrence of non-fatal myocardial infarction [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Time to first occurrence of non-fatal stroke [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Time to diagnosis of type 2 diabetes [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Time to first occurrence of any type of cancer [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Time to first occurrence of a composite of obesity related cancer defined by WHO [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Time to first occurrence of knee replacement [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Time to first occurrence of bariatric surgery [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Time to first occurrence of anti-obesity medical treatment [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Time to first occurrence of use of continuous positive airways pressure (CPAP) device [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Total number of myocardial infarctions [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Total number of strokes [ Time Frame: From P-FUa (is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to 120 months) ]Measured in months
- Change in body weight from V-EOT (is the end of treatment visit in SELECT) to biannual assessments, (year 1-10) [ Time Frame: From V-EOT (is the end of treatment visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to120 months) ]Measured in Kg
- Change in Patient reported quality of life questionnaire (EQ-5D-5L) from V-EOT (is the end of treatment visit in SELECT) to biannual assessments, (year 1-10) [ Time Frame: From V-EOT (is the end of treatment visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to120 months) ]EQ-5D-5L score The EQ-5D-5L questionnaire will be used to estimate the impact on subjects' health-related quality of life and provides a description of subjects' problems by dimensions (descriptive system), a score for overall self-rated health (visual analogue scale [VAS]) as well as an index score (EQ-5D-5L index). EQ-5D index score range: 0 to 1 and EQ-5D-VAS: range 0 to 100. A higher score indicates better self reported health status.
- Total Days of hospitalisation from P-FU (is the end of trial visit in SELECT) to biannual assessments, (year 1-10) [ Time Frame: From P-FU(is the end of trial visit in SELECT) (Day 1) to End of Study in SELECT-LIFE (up to120 months) ]Days
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 45 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Participants of the SELECT trial (EX9536-4388 ) are invited to transition to SELECT-LIFE (follow-up study) when SELECT ends.
Criteria
Inclusion Criteria:
- Randomized into the SELECT clinical trial (EX9536-4388) and has not withdrawn consent, regardless of level of participation, dose achieved or treatment discontinuation.
- Signed SELECT-LIFE consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
Exclusion criteria:
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04972721
Contacts
| Contact: Novo Nordisk | (+1) 866-867-7178 | clinicaltrials@novonordisk.com |
Locations
Show 38 study locations
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
| Study Director: | Clinical Transparency (dept. 2834) | Novo Nordisk A/S |
| Responsible Party: | Novo Nordisk A/S |
| ClinicalTrials.gov Identifier: | NCT04972721 |
| Other Study ID Numbers: |
EX9536-4750 U1111-1255-5644 ( Other Identifier: World Health Organization (WHO) ) |
| First Posted: | July 22, 2021 Key Record Dates |
| Last Update Posted: | February 29, 2024 |
| Last Verified: | February 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | According to the Novo Nordisk disclosure commitment on novonordisk-trials.com |
| URL: | http://novonordisk-trials.com |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Obesity Overweight Overnutrition Nutrition Disorders Body Weight |